Letter | Published:

High risk of squamous cell carcinoma of the cervix for women with HLA-DQw3

Naturevolume 352pages723725 (1991) | Download Citation

Subjects

Abstract

MANY immune responses are controlled by genes of the major histocompatibility complex (MHC)1. In man these include the loci encoding the HLA-A, -B, -C, -DR, -DQ and -DP antigens, and many diseases have been linked with these2–5. But attempts to identify HLA genes in man that might explain why an immune response against malignant tumours should be ineffective have so far been disappointing, apart from the association reported between the HLA-DR1 antigen and a susceptibility to a rare carcinoma of the thyroid gland6. Here we describe another strong connection between a common malignant tumour and an HLA antigen, namely between HLA-DQw3 and squamous cell carcinoma of the cervix: from the 1988 United States tumour registry, 1 in every 63 newborn girls will develop this invasive cancer7. We found that 88% of 66 patients had the leukocyte antigen HLA-DQw3 when it would normally be expected in only 50% of individuals. In animals the immune system and the MHC act in defence against virally induced tumours, but until now there has been no evidence that they do so in humans8: as squamous cell carcinoma is probably virally induced, our discovery of its association with an HLA antigen will be important to the understanding of the immunogenetic basis of a susceptibility to this tumour.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Klein, J., Juretic, A., Baxevanis, C. N. & Nagy, Z. A. Nature 291, 455–460 (1981).

  2. 2

    Schlosstein, L., Terasaki, P. I., Bluestone, R. & Pearson, C. M. New Engl. J. Med. 288, 704–706 (1973).

  3. 3

    Brewerton, D. A. et al. Lancet i, 904–907 (1973).

  4. 4

    Festenstein, H. Nature 322, 64–67 (1986).

  5. 5

    Tiwari, J. L. & Terasaki, P. I. in HLA and Disease Associations (eds Tiwari, J. L. & Terasaki, P. I.) (Springer, New York, 1985).

  6. 6

    Panza, N. et al. Tissue Antigens 20, 155–158 (1982).

  7. 7

    Barber, H. R. K. in Manual of Gynaecology Oncology (ed. Barber, H. R. K.) 212 (Lippincott, Philadelphia, 1989).

  8. 8

    Lachman, P. J. & Mitchison, N. A. in Clinical Aspects of Immunology (eds Lachmann, P. & Peters, K.) 1263–1278 (Blackwell, Oxford, 1982).

  9. 9

    Park, M. S., Terasaki, P.I., Bernoco D. & Iwaki J. Transplant. Proc. 10, 823–827 (1978).

  10. 10

    Baur, M. P. et al. in Histocompatibility Testing 1984 (eds Albert, E. D. et al.) 333–347 (Springer, Berlin and Heidelberg, 1984).

  11. 11

    Kaufmann, J. F., Auffray, C., Kormann, A. J., Skackelford, D. A. & Strominger, J. Cell 36, 1–13 (1984).

  12. 12

    Bodmer, W. F. et al. in Immunobiology of HLA Vol. 1 (ed. Dupont, B.) 72–79 (Springer, New York, 1989).

  13. 13

    Knowles, R. W. in Immunobiology of HLA Vol. 1 (ed. Dupont, B.) 365–380 (Springer, New York, 1989).

  14. 14

    Bodmer, J. G. et al. Tissue Antigens 35, 1–8 (1990).

  15. 15

    Vega, M. A., Bragado, R. & Ivanyi, P. J. Immunolology 137, 3557–3565 (1986).

  16. 16

    Gissmann, L. & Schneider, A. in Origins of Female Genital Cancer: Virological and Epidemiological aspects (eds zur Hausen, H. & Peto, R.) 217 (Banbury Reports, Cold Spring Harbor Laboratory, New York, 1986).

  17. 17

    zur Hausen, H. Lancet ii, 1370–1372 (1982).

  18. 18

    Kjaer, S. K. et al., Int. J. Cancer 41, 518–524 (1988).

  19. 19

    Kämpgen, E., Burg, G. & Wank, R. Arch. Dermat. 124, 1372–1375 (1988).

  20. 20

    Koenig, U. D., Müller, N. & Scheeweis, K. E. Lancet i, 857 (1976).

  21. 21

    Lilly, F. & Pincus, T. Adv. Cancer Res. 17, 231–277 (1973).

  22. 22

    Chesbro, B. Wehrhy, K. & Stimpfling, J. J. exp. Med. 140, 1457–1467 (1974).

  23. 23

    Lonai, P. & Haran-Ghara, N. Immunogenetics 11, 21–29 (1980).

  24. 24

    Böyum, A. Scand. J. clin. Lab. Invest. 97, 21–28 (1968).

  25. 25

    Julius, M. H., Simpson, E. E. & Herzenberg, L. A. Eur. J. Immunn. 3, 645–648 (1973).

  26. 26

    Johnson, J. P. & Wank, R. J. exp. Med. 160, 1350–1359 (1984).

  27. 27

    Termijtelen, A. et al. Tissue Antigens 16, 140–146 (1980).

  28. 28

    Maeda, H. Tissue Antigens 23, 163–170 (1984).

  29. 29

    Tait, B. D. et al. in Immunobiology of HLA Vol. 1 (ed. Dupont, B.) 269–273 Springer, New York, 1989).

  30. 30

    Johnson, J. P., Nordwig, H. & Wank, R. Tissue Antigens 29, 26–33 (1987).

  31. 31

    Milford, E. L., Park, M. S., Lalouel, J. M. & Kennedy, L. J. in Immunobiology of HLA Vol. 1 (ed. Dupont, B.) 93–106 (Springer, New York, 1989).

  32. 32

    Dunn, O. J. J. Amer. statist. Assoc. 54, 52–64 (1961).

  33. 33

    Haldane, J. B. S. Ann. hum. Genet 20, 309–311 (1956).

Download references

Author information

Affiliations

  1. Institute of Immunology, University of Munich, Goethestrasse 31, D-8000, München, 2

    • Rudolf Wank
    •  & Christoph Thomssen
  2. Department of Obstetrics and Gynaecology, Technische Universitat, D-8000, Munchen, 80, Germany

    • Rudolf Wank
    •  & Christoph Thomssen

Authors

  1. Search for Rudolf Wank in:

  2. Search for Christoph Thomssen in:

About this article

Publication history

Received

Accepted

Issue Date

DOI

https://doi.org/10.1038/352723a0

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.